Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease.

Authors: Plu-Bureau G, Le MG, Thalabard JC, Sitruk-Ware R, Mauvais-Jarvis P. Publication Year: 1999 Citation: Cancer Detect Prev 1999;23(4):290-6. This cohort study followed 1150 premenopausal French women diagnosed with benign breast disease. Topical progesterone cream, a common treatment for mastalgia in Europe, had been prescribed to 58% of the women. Follow-up accumulated 12,462 person-years. There …

Pregnancy, progesterone and progestins in relation to breast cancer risk.

Authors: Campagnoli C, Abba C, Ambroggio S, Peris C. Publication Year: 2005 Citation: J Steroid Biochem Mol Biol 2005; 97(5):441-50. The authors review recent findings that show that the production of progesterone during pregnancy and the use of bioidentical progesterone in hormone therapy do not increase breast cancer risk, and can even protect against the …

Osteoporosis reversal; the role of progesterone.

Author: Lee JR. Publication Year: 1990 Citation: International Clinical Nutrition Review 1990;10(3):384-91. Transdermal progesterone supplementation with and without conjugated estrogens was evaluated in a clinical setting using 100 women aged 38 to 83 years. The average time from onset of menopause was 16 years. 63 women were followed for three years with dual photon absorptiometry. …

Biologic effects of transdermal estradiol.

Authors: Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Publication Year: 1986 Citation: N Engl J Med 1986 Jun 19;314(25):1615-20. Twenty-three postmenopausal women were randomly assigned to use of transdermal estradiol in four increasing doses (25, 50, 100, 100 micrograms per 24 hours) …

Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women.

Authors: Ettinger B, Genant HK, Steiger P, Madvig P. Publication Year: 1992 Citation: Am J Obstet Gynecol 1992;166(2):479-88. The authors evaluated the effects of 17 beta-estradiol (E2) in a randomized, double-blind, dose ranging study of 41 postmenopausal women conducted in 2 phases. Phase one included phased E2 doses (0.5mg, 1.0mg, 2.0mg) plus calcium supplementation (to …